Medicus Pharma Ltd Quick Ratio (MDCX) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Medicus Pharma Ltd   (NASDAQ: MDCX)

Medicus Pharma Ltd 's Quick Ratio

MDCX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2026, Quick Ratio deteriorated to 0.52 below Medicus Pharma Ltd 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 326 other companies have achieved higher Quick Ratio than Medicus Pharma Ltd in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 1499 to 1694.

Explain Quick Ratio?
How much Cash & cash equivalents MDCX´s has?
What are MDCX´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MDCX/financial-strength
https://api.csimarket.com/api/v1/companies/MDCX/fundamentals
https://api.csimarket.com/api/v1/companies/MDCX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
MDCX Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -8.58 %
Y / Y Cash & cash equivalent Change -42.05 %
Quick Ratio MRQ 0.52
MDCX's Total Ranking # 1694
Seq. Current Liabilities Change -10.13 %
Seq. Cash & cash equivalent Change -66.92 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 327
Healthcare Sector # 579
Overall Market # 1694


Quick Ratio Statistics
High Average Low
3.97 1.53 0.81
(Dec 31 2023)   (Sep 30 2025)




Financial Statements
Medicus Pharma Ltd 's Current Liabilities $ 10 Millions Visit MDCX's Balance sheet
Medicus Pharma Ltd 's Cash & cash equivalent $ 5 Millions Visit MDCX's Balance sheet
Source of MDCX's Sales Visit MDCX's Sales by Geography


Cumulative Medicus Pharma Ltd 's Quick Ratio

MDCX's Quick Ratio for the trailling 12 Months

MDCX Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 46.82 %
Y / Y Cash & cash equivalent TTM Growth 33.18 %
Quick Ratio TTM 0.97
Total Ranking TTM # 3951
Seq. Current Liabilities TTM Growth -2.45 %
Seq. Cash & cash equivalent TTM Growth -9.36 %


On the trailing twelve months basis In spite of the year on year decrease in MDCX's Current Liabilities to $9.74 millions, cumulative Quick Ratio to 0.97 below the MDCX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 436 other companies have achieved higher Quick Ratio than Medicus Pharma Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2826 to 3951.

Explain Quick Ratio?
How much Cash & cash equivalents MDCX´s has?
What are MDCX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 437
Healthcare Sector # 893
Within the Market # 3951


trailing twelve months Quick Ratio Statistics
High Average Low
1.07 1 0.95
(Sep 30 2025)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Palatin Technologies Inc   1.41 $ 3.740  Millions$ 2.659  Millions
Arbutus Biopharma Corp  1.39 $ 337.490  Millions$ 241.933  Millions
Pulmatrix Inc   1.37 $ 1.398  Millions$ 1.017  Millions
Compass Pathways Plc  1.36 $ 443.979  Millions$ 325.863  Millions
Sarepta Therapeutics Inc   1.34 $ 878.776  Millions$ 656.353  Millions
Zai Lab Limited  1.32 $ 559.658  Millions$ 424.249  Millions
Urogen Pharma Ltd   1.31 $ 96.901  Millions$ 74.031  Millions
Fortress Biotech Inc   1.29 $ 152.186  Millions$ 118.375  Millions
Ani Pharmaceuticals Inc  1.28 $ 420.758  Millions$ 328.717  Millions
Vertex Pharmaceuticals Inc  1.26 $ 6,303.300  Millions$ 5,000.300  Millions
Metavia Inc   1.24 $ 8.780  Millions$ 7.060  Millions
Nature s Sunshine Products inc   1.22 $ 89.377  Millions$ 73.488  Millions
Moleculin Biotech Inc   1.19 $ 7.287  Millions$ 6.135  Millions
Ovid Therapeutics Inc   1.16 $ 13.811  Millions$ 11.858  Millions
Werewolf Therapeutics Inc   1.16 $ 41.870  Millions$ 35.994  Millions
Filana Therapeutics Inc   1.12 $ 46.990  Millions$ 41.946  Millions
Connect Biopharma Holdings Limited  1.07 $ 16.503  Millions$ 15.495  Millions
Phathom Pharmaceuticals Inc   1.06 $ 184.558  Millions$ 174.902  Millions
Pmgc Holdings Inc   1.05 $ 13.668  Millions$ 13.026  Millions
Eton Pharmaceuticals Inc   1.03 $ 55.628  Millions$ 54.095  Millions
Oragenics Inc   1.02 $ 2.227  Millions$ 2.189  Millions
Geovax Labs Inc   1.01 $ 2.151  Millions$ 2.135  Millions
Akebia Therapeutics Inc   0.98 $ 159.254  Millions$ 162.349  Millions
Acadia Pharmaceuticals Inc   0.97 $ 322.365  Millions$ 332.217  Millions
Alkermes Plc   0.97 $ 631.314  Millions$ 651.933  Millions
Theriva Biologics inc   0.97 $ 8.473  Millions$ 8.779  Millions
Imunon Inc   0.95 $ 4.039  Millions$ 4.239  Millions
Geron Corporation  0.94 $ 69.794  Millions$ 74.248  Millions
Mirum Pharmaceuticals Inc   0.86 $ 243.188  Millions$ 283.080  Millions
Amphastar Pharmaceuticals Inc   0.86 $ 262.786  Millions$ 306.303  Millions

Date modified: 2026-11-07T10:28:44+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.